Blueshift Asset Management, LLC Immuno Gen, Inc. Transaction History

Blueshift Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $83,399 - $120,445	18,616 New	18,616 $89,000
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $180,787 - $330,583	-57,393 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.26 - $7.48 $244,494 - $429,299	57,393 New	57,393 $273,000
Q4 2021 Feb 11, 2022	SELL	$4.75 - $7.5 $222,195 - $350,835	-46,778 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.02 - $6.59 $128,537 - $168,736	25,605 Added 120.93%	46,778 $265,000
Q2 2021 Aug 13, 2021	SELL	$5.79 - $8.6 $31,653 - $47,016	-5,467 Reduced 20.52%	21,173 $140,000
Q1 2021 May 06, 2021	BUY	$6.5 - $10.53 $173,160 - $280,519	26,640 New	26,640 $216,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.